222 related articles for article (PubMed ID: 34076905)
1. ELISPOT assay of interferon-γ secretion for evaluating human cytomegalovirus reactivation risk in allo-HSCT recipients.
Liang H; Xia J; Zhang R; Yang B; Wu J; Gui G; Huang Y; Chen X; Yang R; Wang H; Gong S; Fan J
J Med Virol; 2021 Nov; 93(11):6301-6308. PubMed ID: 34076905
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of human cytomegalovirus-specific CD8+ T-cells in allogeneic haematopoietic stem cell transplant recipients using pentamer and interferon-γ-enzyme-linked immunospot assays.
Liu A; Ma Y; Wu W; Chen X; Huang Y; Hu J; Liang H; Wang H; Yang R; Fan J
J Clin Virol; 2013 Oct; 58(2):427-31. PubMed ID: 23910932
[TBL] [Abstract][Full Text] [Related]
3. Normalizing ELISPOT responses to T-cell counts: a novel approach for quantification of HCMV-specific CD4(+) and CD8(+) T-cell responses in kidney transplant recipients.
Calarota SA; Chiesa A; Scaramuzzi L; Adzasehoun KM; Comolli G; Mangione F; Esposito P; Baldanti F
J Clin Virol; 2014 Sep; 61(1):65-73. PubMed ID: 24961915
[TBL] [Abstract][Full Text] [Related]
4. Reconstitution of cytomegalovirus-specific T-cell response in allogeneic hematopoietic stem cell recipients: the contribution of six frequently recognized, virus-encoded ORFs.
Nemeckova S; Krystofova J; Babiarova K; Hainz P; Musil J; Sroller V; Maly M; Stastna-Markova M
Transpl Infect Dis; 2016 Jun; 18(3):381-9. PubMed ID: 27061389
[TBL] [Abstract][Full Text] [Related]
5. The Ability of a Cytomegalovirus ELISPOT Assay to Predict Outcome of Low-Level CMV Reactivation in Hematopoietic Cell Transplant Recipients.
El Haddad L; Ariza-Heredia E; Shah DP; Jiang Y; Blanchard T; Ghantoji SS; El Chaer F; El-Haddad D; Prayag A; Nesher L; Rezvani K; Shpall E; Chemaly RF
J Infect Dis; 2019 Feb; 219(6):898-907. PubMed ID: 30295846
[TBL] [Abstract][Full Text] [Related]
6. Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8+ and CD4+ T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients.
Tormo N; Solano C; Benet I; Clari MA; Nieto J; de la Cámara R; López J; López-Aldeguer N; Hernández-Boluda JC; Remigia MJ; Garcia-Noblejas A; Gimeno C; Navarro D
Bone Marrow Transplant; 2010 Mar; 45(3):543-9. PubMed ID: 19617905
[TBL] [Abstract][Full Text] [Related]
7. Human cytomegalovirus specific CD8(+) T lymphocytes display interferon-gamma secretion impairment in kidney transplant recipients with pp65 antigenemia.
Yang R; Xia T; Xu G; Li Z; Ying Z; Xu X
Transplant Proc; 2008 Dec; 40(10):3500-4. PubMed ID: 19100424
[TBL] [Abstract][Full Text] [Related]
8. Early immune surveillance to predict cytomegalovirus outcomes after allogeneic hematopoietic stem cell transplantation.
Xia J; Li X; Gui G; Wu J; Gong S; Shang Y; Fan J
Front Cell Infect Microbiol; 2022; 12():954420. PubMed ID: 35992173
[TBL] [Abstract][Full Text] [Related]
9. Herpesvirus infections in hematopoietic stem cell transplant recipients seropositive for human cytomegalovirus before transplantation.
Fan J; Jing M; Yang M; Xu L; Liang H; Huang Y; Yang R; Gui G; Wang H; Gong S; Wang J; Zhang X; Zhao H; Gao H; Dong H; Ma W; Hu J
Int J Infect Dis; 2016 May; 46():89-93. PubMed ID: 27057748
[TBL] [Abstract][Full Text] [Related]
10. Secretion of IFN-γ by specific T cells in HCMV infection.
Liang H; Gong S; Gui G; Wang H; Jiang L; Li X; Fan J
Heliyon; 2024 Mar; 10(6):e28177. PubMed ID: 38533049
[TBL] [Abstract][Full Text] [Related]
11. Utility of the Enzyme-Linked Immunospot Interferon-γ-Release Assay to Predict the Risk of Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients.
Nesher L; Shah DP; Ariza-Heredia EJ; Azzi JM; Siddiqui HK; Ghantoji SS; Marsh LY; Michailidis L; Makedonas G; Rezvani K; Shpall EJ; Chemaly RF
J Infect Dis; 2016 Jun; 213(11):1701-7. PubMed ID: 26908740
[TBL] [Abstract][Full Text] [Related]
12. Reconstitution of CMV pp65 and IE-1-specific IFN-γ CD8(+) and CD4(+) T-cell responses affording protection from CMV DNAemia following allogeneic hematopoietic SCT.
Tormo N; Solano C; Benet I; Nieto J; de la Cámara R; López J; Garcia-Noblejas A; Muñoz-Cobo B; Costa E; Clari MA; Hernández-Boluda JC; Remigia MJ; Navarro D
Bone Marrow Transplant; 2011 Nov; 46(11):1437-43. PubMed ID: 21243030
[TBL] [Abstract][Full Text] [Related]
13. Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation.
Hebart H; Daginik S; Stevanovic S; Grigoleit U; Dobler A; Baur M; Rauser G; Sinzger C; Jahn G; Loeffler J; Kanz L; Rammensee HG; Einsele H
Blood; 2002 May; 99(10):3830-7. PubMed ID: 11986243
[TBL] [Abstract][Full Text] [Related]
14. Comparison of cytomegalovirus (CMV) enzyme-linked immunosorbent spot and CMV quantiferon gamma interferon-releasing assays in assessing risk of CMV infection in kidney transplant recipients.
Abate D; Saldan A; Mengoli C; Fiscon M; Silvestre C; Fallico L; Peracchi M; Furian L; Cusinato R; Bonfante L; Rossi B; Marchini F; Sgarabotto D; Rigotti P; Palù G
J Clin Microbiol; 2013 Aug; 51(8):2501-7. PubMed ID: 23678073
[TBL] [Abstract][Full Text] [Related]
15. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
Fleming T; Dunne J; Crowley B
J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
[TBL] [Abstract][Full Text] [Related]
16. Expansion of human cytomegalovirus (HCMV) immediate-early 1-specific CD8+ T cells and control of HCMV replication after allogeneic stem cell transplantation.
Sacre K; Nguyen S; Deback C; Carcelain G; Vernant JP; Leblond V; Autran B; Dhedin N
J Virol; 2008 Oct; 82(20):10143-52. PubMed ID: 18684826
[TBL] [Abstract][Full Text] [Related]
17. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
[TBL] [Abstract][Full Text] [Related]
18. Identifying Cytomegalovirus Complications Using the Quantiferon-CMV Assay After Allogeneic Hematopoietic Stem Cell Transplantation.
Yong MK; Cameron PU; Slavin M; Morrissey CO; Bergin K; Spencer A; Ritchie D; Cheng AC; Samri A; Carcelain G; Autran B; Lewin SR
J Infect Dis; 2017 Jun; 215(11):1684-1694. PubMed ID: 28431019
[TBL] [Abstract][Full Text] [Related]
19. Immunomonitoring via ELISPOT Assay Reveals Attenuated T-Cell Immunity to CMV in Immunocompromised Liver-Transplant Patients.
Traska AK; Nowacki TM; Vollenberg R; Rennebaum F; Meier JA; Schomacher T; Reinartz Groba SN; Fischer J; Trebicka J; Tepasse PR
Cells; 2024 Apr; 13(9):. PubMed ID: 38727277
[TBL] [Abstract][Full Text] [Related]
20. Rapid monitoring of immune reconstitution after allogeneic stem cell transplantation--a comparison of different assays for the detection of cytomegalovirus-specific T cells.
Abu-Khader A; Krause S
Eur J Haematol; 2013 Dec; 91(6):534-45. PubMed ID: 23952609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
